Drusenoid pigment epithelial detachment volume is associated with a decrease in best‐corrected visual acuity and central retinal thickness: the Norwegian Pigment Epithelial Detachment Study (NORPED) report no. 1

The purpose of the study was to evaluate changes in best corrected visual acuity, central retinal thickness, area and flow in the neovascular membrane and to compare therapeutic outcomes from baseline in patients who received three doses of Beovu (brolucizumab) at three-month follow-up. Material and methods: A prospective observational study conducted at the Prof. K. Gibiński University Clinical Center of the Medical University of Silesia in Katowice. Eight patients with exudative form of age-related macular degeneration (AMD) were observed. Results: The mean best corrected visual acuity (BCVA) outcome increased with each subsequent visit. The mean central retinal thickness (CRT) result also improved (decreased) with each subsequent visit, except for the last measurement. A statistically significant change in neovascular membrane area was observed after the first injection. In further treatment, the membrane area underwent changes that were not statistically significant. A statistically significant change in neovascular membrane flow was demonstrated after the first and second injections. Discussion: Our study confirmed the efficacy of brolucizumab in the treatment of patients with exudative AMD in terms of improvements in best corrected visual acuity (BCVA), central retinal thickness (CRT), neovascular membrane area, and neovascular membrane flow area.

Download Full-text

Anti-VEGF-Therapie bei myopischer choroidaler Neovaskularisation: Langzeitergebnisse

Karger Kompass Ophthalmologie ◽

10.1159/000370022 ◽

2015 ◽

Vol 1 (1) ◽

pp. 38-39

Keyword(s):

Visual Acuity ◽

Choroidal Neovascularization ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

Myopic Choroidal Neovascularization ◽

Retrospektive Analyse ◽

Corrected Visual Acuity ◽

Anti Vegf ◽

Best Corrected Visual Acuity

Ziel: Beurteilung der mittel- und langfristigen Wirksamkeit von Anti-VEGF-Wirkstoffen in der Behandlung der choroidalen Neovaskularisation infolge einer pathologischen Myopie (myopic choroidal neovascularization; mCNV).Methoden: Retrospektive Analyse von mCNV-Patienten, die 2 Jahre oder länger mit einer intravitrealen Anti-VEGF-Therapie behandelt worden waren. Wir verglichen die Sehschärfe mit bester Korrektur (best-corrected visual acuity; BCVA) sowie die zentrale Netzhaut-Dicke (central retinal thickness; CRT) vor und nach der Behandlung. Die Anzahl der Injektionen pro Jahr wurde ebenfalls erfasst.Ergebnisse: Auswertungen der Ergebnisse erfolgten nach 2 Jahren für 67 Augen, nach 3 Jahren für 52 Augen, nach 4 Jahren für 28 Augen und nach 5 Jahren für 13 Augen. Die mittlere Veränderung der BCVA gegenüber dem Ausgangswert war nach 2 Jahren signifikant (+8,6 Buchstaben; p < 0,001); diese Verbesserung blieb über einen Zeitraum von 5 Jahren signifikant stabil bestehen. Die mittlere CRT nahm im Verlauf signifikant ab; der Tiefstwert war nach 2 Jahren erreicht (-104,0 μm; p < 0,001). Die mittlere Anzahl der Injektionen betrug im 1. Jahr 5,2 und ging in den nachfolgenden Jahren zurück (p < 0,001).Schlussfolgerung: In der hier beschriebenen Untergruppe von mCNV-Patienten war die intravitreale Anti-VEGF-Therapie über einen Zeitraum von 5 Jahren wirksam, wobei sich der BCVA-Wert fortwährend erhöhte.Übersetzung aus Ophthalmologica 2014;232:57-63 (DOI: 10.1159/000360307)

Download Full-text

Functional and morphological retinal impairment following resolved chronic central serous chorioretinopathy

10.21203/rs.2.29/v1 ◽

2018 ◽

Author(s):

Maciej Gawęcki ◽

Agnieszka Jaszczuk-Maciejewska ◽

Anna Jurska-Jaśko ◽

Małgorzata Kneba ◽

Andrzej Grzybowski

Keyword(s):

Visual Acuity ◽

Central Serous Chorioretinopathy ◽

Retinal Thickness ◽

Subretinal Fluid ◽

Central Retinal Thickness ◽

Morphological Parameters ◽

Chronic Central Serous Chorioretinopathy ◽

Micropulse Laser ◽

Corrected Visual Acuity ◽

Best Corrected Visual Acuity

Abstract Purpose Central serous chorioretinopathy is a complex ocular entity that, in its chronic form, can lead to serious visual impairment and morphological damage to the retina. The aim of the current retrospective study was to evaluate the damage present after long-standing but resolved central serous chorioretinopathy. Correlations between measurable factors—for example, duration of the disease, baseline retinal morphological parameters, or patient age and/or their degree of impairment—were also assessed. Materials and methods Thirty-two eyes with chronic central serous chorioretinopathy in which complete resolution of subretinal fluid was achieved after subthreshold micropulse laser treatment were analyzed according to final best-corrected visual acuity and retinal morphological parameters as measured by spectral optical coherence tomography with angiography option (OCTA). Results were compared with the outcomes of a control group. Statistical analysis included regarding correlation between final visual acuity and final central retinal thickness and retinal and functional parameters prior to treatment. Results Final best-corrected visual acuity after chronic central serous chorioretinopathy was 0.23 logMAR (0.6 Snellen) and central retinal thickness was 39.32 µm smaller than in controls. No correlation was found between final visual acuity and retinal thickness and duration of the disease, patient age, and baseline morphological retinal parameters. OCTA scans revealed impaired choroidal perfusion even following resolution of the disease. Conclusion Chronic central serous chorioretinopathy is a potentially damaging clinical entity that results in serious visual impairment, retinal thinning, and choroidal flow defects. No significant correlation between duration of central serous chorioretinopathy and amount of visual deficit has been found, therefore it is possible that the biggest damage occurs within the first months of active chorioretinopathy. Keywords: chronic central serous chorioretinopathy, micropulse laser, central retinal thickness, subretinal fluid

Download Full-text

Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency

European Journal of Ophthalmology ◽

10.1177/1120672120901691 ◽

2020 ◽

pp. 112067212090169 ◽

Cited By ~ 1

Author(s):

Olufemi E Adams ◽

Sidney A Schechet ◽

Seenu M Hariprasad

Keyword(s):

Visual Acuity ◽

Intraocular Pressure ◽

Macular Edema ◽

Diabetic Macular Edema ◽

Retinal Thickness ◽

Fluocinolone Acetonide ◽

Central Retinal Thickness ◽

Corrected Visual Acuity ◽

Persistent Diabetic Macular Edema ◽

Best Corrected Visual Acuity

Objective: To evaluate, in the setting of persistent diabetic macular edema, the impact that continuous fluocinolone acetonide delivery has on treatment burden, visual acuity, central retinal thickness, and intraocular pressure. Materials and methods: A single-center, retrospective, cohort study of patients with persistent diabetic macular edema, previously treated with anti–vascular endothelial growth factor injections, dexamethasone implants, or focal laser, who were subsequently treated with fluocinolone acetonide was conducted. All retinal visits were analyzed prior to fluocinolone acetonide, until the most recent follow-up visit. Primary outcomes were pre– and post–fluocinolone acetonide changes in the best-corrected visual acuity and number of treatments required for diabetic macular edema. Secondary outcomes included changes in the central retinal thickness and intraocular pressure. Results: A total of 19 eyes with persistent diabetic macular edema were included and followed for a mean (SD) of 399.3 (222.9) days. Post–fluocinolone acetonide, the mean best-corrected visual acuity improved by 0.4 ETDRS letters for all eyes ( p = 0.895) and the central retinal thickness decreased by 34.2 µm ( p = 0.077). After fluocinolone acetonide, the number of treatments decreased from an average of one treatment every 2.7 months to one every 6 months ( p = 0.009). Furthermore, post–fluocinolone acetonide, 10/19 eyes (52.6%) did not require additional treatment due to a dry macula, and those who did experienced a non-statistically significant reduction of treatments, from one every 2.6 months pre–fluocinolone acetonide, to one every 2.8 months post–fluocinolone acetonide ( p = 0.622). Conclusions: In the setting of persistent diabetic macular edema, fluocinolone acetonide significantly reduces the therapeutic burden, while maintaining best-corrected visual acuity and improving the central retinal thickness. In patient-centered discussions, judiciously employing fluocinolone acetonide should be performed to mitigate this therapeutic burden for patients.

Download Full-text

Safety of various parameter sets with navigated microsecond pulsing laser in central serous chorioretinopathy

International Journal of Retina and Vitreous ◽

10.1186/s40942-021-00335-3 ◽

2021 ◽

Vol 7 (1) ◽

Author(s):

Jay Chhablani ◽

Gagan Kalra ◽

Lubna Alkwatli ◽

Bernd Fassbender ◽

Francesca Amoroso ◽

...

Keyword(s):

Visual Acuity ◽

Adverse Events ◽

Central Serous Chorioretinopathy ◽

Retinal Thickness ◽

Subretinal Fluid ◽

Central Retinal Thickness ◽

Duration Of Symptoms ◽

Corrected Visual Acuity ◽

Best Corrected Visual Acuity

Abstract Background Subthreshold microsecond pulsing laser is an increasingly common treatment approach for central serous chorioretinopathy. However, there is no literature available on the safety of microsecond laser using different fluence settings in this disease. While many publications can be obtained from conventional microsecond pulsing lasers, few parameter sets are published with the navigated microsecond pulsing laser. Therefore, this study aims to investigate the safety of different parameter sets in subthreshold microsecond pulsing laser treatments. Methods In this retrospective chart review, consecutive patients with central serous chorioretinopathy (> 3 months duration of symptoms) treated with navigated subthreshold microsecond pulsing laser and a follow up of at least five months after microsecond laser application were included. For each patient, the treatment parameters, plan layout, and adverse events related to laser were evaluated. Secondary outcomes included best-corrected visual acuity and anatomical improvements (central retinal thickness). Results One hundred and one eyes were included in the observation and followed for a mean of 10 months (range 5–36). Although a larger range of parameter sets and fluence settings have been used, no patient demonstrated adverse events from navigated microsecond pulsing laser. While 88% of the cases demonstrated stability, 13 cases lost five or more letters due to the persistence of the subretinal fluid. In mean, a best-corrected visual acuity improvement of 0.07logMar (± 0.2) was seen (p = 0.02). In 51% of the patients, a statistically significant improvement of the central retinal thickness was noted at the last follow-up with a mean thickness reduction of 70 µm (± 143) (p < 0.01). Conclusion In conclusion, none of the used parameter sets lead to tissue damage (when using a cautious titration) and, in summary, lead to an improvement in subretinal fluid and improvement in visual acuity. However, further prospective studies are needed to correctly identify the dependency of the treatment strategy on the outcome criteria.

Download Full-text

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularizations Associated with Pathologic Myopia: A Prospective Study

Ophthalmologica ◽

10.1159/000369397 ◽

2014 ◽

Vol 233 (1) ◽

pp. 2-7 ◽

Cited By ~ 2

Author(s):

Nataliya V. Pasyechnikova ◽

Volodymyr O. Naumenko ◽

Andrii R. Korol ◽

Oleg S. Zadorozhnyy ◽

Taras B. Kustryn ◽

...

Keyword(s):

Visual Acuity ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

Pathologic Myopia ◽

Intravitreal Ranibizumab ◽

Corrected Visual Acuity ◽

The Mean ◽

A Prospective Study ◽

Best Corrected Visual Acuity

Purpose: It was the aim of this study to determine the efficacy of intravitreal ranibizumab as treatment of choroidal neovascularizations associated with pathologic myopia. Materials and Methods: In an uncontrolled, prospective time series cohort study, 65 eyes of 64 consecutive patients with choroidal neovascularization associated with pathologic myopia were treated with intravitreal ranibizumab and observed over 12 months. The change in best-corrected visual acuity (BCVA) at 6 and 12 months served as primary end point. Safety, central retinal thickness, neovascularization activity on fluorescein angiography and the number of ranibizumab injections were secondary end points. Results: BCVA improved significantly throughout the follow-up (p = 0.001). The mean BCVA was 0.2 at baseline (SD 0.13) and 0.4 at 12 months (SD 0.21). Improvement was strongest within the first 3 months (p = 0.0001). The mean central retinal thickness showed a reduction from 313 μm (SD 82) to 243.5 μm (SD 31; p = 0.0001). Conclusion: Intravitreal ranibizumab offers a safe and effective treatment for choroidal neovascularizations in pathologic myopia.

Download Full-text

Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China

BMC Ophthalmology ◽

10.1186/s12886-021-01877-8 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Xin Nie ◽

Yulong Wang ◽

Hong Yi ◽

Yanbin Qiao

Keyword(s):

Visual Acuity ◽

Adverse Events ◽

Real World ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

Pathological Myopia ◽

Corrected Visual Acuity ◽

Real World Setting ◽

The Mean ◽

Best Corrected Visual Acuity

Abstract Background To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a follow up of 12 months. After the first injection, administration of conbercept followed a pro re nata (PRN) regimen. Outcomes included best corrected visual acuity (BCVA), central retinal thickness (CRT), CNV size, the total number of treatments, and adverse events. Results The mean patient age was 55.88 ± 16.17 years, and the mean eye spherical equivalent was − 8.72 ± 3.75 D. The mean number of IVC over 12 months was 2.12 ± 0.69. Overall, best-corrected visual acuity(BCVA)improved from 0.86 ± 0.33 logMAR at baseline to 0.44 ± 0.32 logMAR at month 12 (p < 0.001), mean improvement of vision was 4.12 ± 2.69 lines. Mean central retinal thickness reduced from 285.9 ± 104.6 µm at baseline to 192.1 ± 97.5 µm at month 12 (p < 0.001). Mean CNV size decreased from 0.52 ± 0.38 mm2 at baseline to 0.31 ± 0.19 mm2 at 12 months (p < 0.05). All the 34 eyes had reduced or stable size of CNV. Thirty-two eyes (94.12 %) showed the absence of CNV leakage at the end of the study period. No severe systemic or ocular adverse events were observed. Conclusions Intravitreal conbercept 0.5 mg was safe and effective for treatment of myopic CNV over 12 months in a real-world setting.

Download Full-text

Effect of Supra-Choroidal Triamcinolone Injection on Best-Corrected Visual Acuity and Central Retinal Thickness in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Pakistan Journal of Ophthalmology ◽

10.36351/pjo.v38i1.1347 ◽

2021 ◽

Vol 38 (1) ◽

Author(s):

Irfan Muslim ◽

Nasir Chaudhry ◽

Rana Muhammad Mohsin Javed

Keyword(s):

Visual Acuity ◽

Macular Edema ◽

Retinal Vein Occlusion ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

P Value ◽

Vein Occlusion ◽

Corrected Visual Acuity ◽

Triamcinolone Injection ◽

Best Corrected Visual Acuity

Purpose: To find out the effect of suprachoroidal Triamcinolone injection on best corrected visual acuity (BCVA) and central retinal thickness (CRT) in patients with macular edema secondary to retinal vein occlusion. Study Design: Interventional case series. Place and Duration of Study: College of Ophthalmology and Allied vision Sciences, Ophthalmology department, Unit II Mayo hospital, Lahore, from September 2019 to January 2020. Methods: This study included 45 patients diagnosed with unilateral, retinal vein occlusion associated with macular edema. Patients with previous anti-vascular endothelial growth factor injection or any steroid injection received in the last 3 months or macular edema due to any other cause were excluded from the study. Only one eye of each patient was enrolled. The patients were treated with suprachoroidal triamcinolone injection (4 mg/100µL concentration). Patients with baseline central retinal thickness (CRT) of > 300 µm were included in the study. Serial changes in this parameter were evaluated at 1 week, 1 month and 3?months after suprachoroidal triamcinolone injection. Final CRT and Best-corrected visual acuity (BCVA) was recorded after three months. Results: Out of 45 patients, 26 (57.7%) were males and 19 (42.2%) were females. Majority of the patients (35.4%) were 51–60 years old. During first week the visual acuity was 0.321 ± 0.273 LogMAR, after one month it was 0.468 ± 0.291 and 0.406 ± 0.318 after 03 months with a p value of 0.003. After three months significant decrease in CRT was observed. With a p-value of 0.002. Conclusions: Suprachoroidal injection significantly improves BCVA and decreases CRT in patients with macular edema due to retinal vein Occlusion. Keywords: Retinal vein occlusion, suprachoroidal injection, triamcinolone acetonide.

Download Full-text

Structural and functional macular changes after cataract surgery in diabetic patients

Medicinski pregled ◽

10.2298/mpns2010284s ◽

2020 ◽

Vol 73 (9-10) ◽

pp. 284-290

Author(s):

Sasa Smoljanovic-Skocic ◽

Bojana Markic ◽

Sanela-Sanja Burgic ◽

Milka Mavija ◽

Stefan Brunet

Keyword(s):

Optical Coherence Tomography ◽

Visual Acuity ◽

Cataract Surgery ◽

Retinal Thickness ◽

Central Retinal Thickness ◽

Diabetic Patients ◽

Optical Coherence ◽

Corrected Visual Acuity ◽

Group I ◽

Best Corrected Visual Acuity

Introduction. In recent years, the number of diabetic patients requiring cataract surgery has been on the rise. The aim of this study was to examine the effects of cataract surgery on visual acuity and changes in the central retinal thickness in diabetic patients with and without retinopathy, in relation to the duration of the disease, type of therapy, and the level of glycated hemoglobin and serum lipids. Material and Methods. The prospective study included 51 eyes of 34 patients divided into three groups. Preoperatively, all patients underwent best-corrected visual acuity evaluation with Snellen chart, cataract grading using lens opacities classification system III, as well as fundus examination and optical coherence tomography. Postoperative follow-up visits were scheduled after the first, fourth, sixth, eighth, and twelfth weeks after which the patients underwent best-corrected visual acuity evaluation and optical coherence tomography. The obtained values were statistically processed and analyzed in relation to the duration of the disease, the type of therapy, and the level of glycated hemoglobin and serum lipids. Results. Of 51 eyes, 5.9% developed macular edema during the fourth postoperative week with central retinal thickness > 310 ?m. Subclinical central retinal thickness changes were registered in all groups with the highest values in group I (diabetics with retinopathy) in the sixth postoperative week. The average value of central retinal thickness in group I was 256 ? 11 ?m at baseline and 273 ? 11 ?m in week 6. The best-corrected visual acuity improved in all groups, without changes in central retinal thickness. Conclusion. Good visual acuity and absence of significant changes in macular thickness are helpful when making the decision to perform cataract surgery in patients with diabetes. Postoperative follow-up visits should include optical coherence tomography in addition to standard procedures.

Download Full-text

Intravitreal Conbercept for choroidal neovascularisation secondary to pathological myopia in real-life setting in China

10.21203/rs.2.24130/v1 ◽

2020 ◽

Author(s):

Xin Nie ◽

Yulong Wang ◽

Hong Yi ◽

yanbin qiao

Keyword(s):

Visual Acuity ◽

Retinal Thickness ◽

Real Life ◽

Central Retinal Thickness ◽

Pathological Myopia ◽

Corrected Visual Acuity ◽

Real Life Setting ◽

The Mean ◽

Best Corrected Visual Acuity

Abstract Background: To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). Methods: A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a follow up of 12 months. After the first injection, administration of conbercept followed a pro re nata (PRN) regimen. Outcomes included best corrected visual acuity (BCVA), central retinal thickness (CRT), CNV size, the total number of treatments, and adverse events. Results: The mean patient age was 55.88 ± 16.17 years, and mean eye spherical equivalent was − 8.72 ± 3.75 D. The mean number of IVC over 12 months was 2.12 ± 0.69. Overall, best-corrected visual acuity（BCVA）improved from 0.86 ± 0.33 logMAR at baseline to 0.44 ± 0.32 logMAR at month 12 ( P < 0.001 ), mean improvement of vision was 4.12 ± 2.69 Snellen lines . Mean central retinal thickness reduced from 285.9 ± 104.6 μm at baseline to 192.1 ± 97.5 μm at month 12 (P < 0.001). Mean CNV size decreased from 0.52 ± 0.38 mm 2 at baseline to 0.31 ± 0.19 mm 2 at 12 months (P < 0.05). All the 34 eyes had reduced or stable size of CNV, thirty-two eyes (94.12%) showed absence of CNV leakage at the end of the study period. No severe complications were observed. Conclusion: Intravitreal conbercept 0.5mg was safe and effective for treatment of myopic CNV over 12 months in real-life setting.

Download Full-text